A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19

The systemic inflammatory response seen in patients with severe COVID-19 shares many similarities with the changes observed in hemophagocytic lymphohistiocytosis (HLH); a disease characterized by excessive immune activation. Many patients with severe COVID qualify for a diagnosis of HLH. Etoposide,...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpin, Meredith, Lerner, Adam, Sagar, Manish, Govender, Praveen, Shah, Bhavesh, Weinberg, Janice, Sarosiek, Shayna, Sloan, J. Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274992/
https://www.ncbi.nlm.nih.gov/pubmed/37333402
http://dx.doi.org/10.1101/2023.06.05.23290969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274992/
https://www.ncbi.nlm.nih.gov/pubmed/37333402
http://dx.doi.org/10.1101/2023.06.05.23290969

Ejemplares similares